此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

前瞻性随机化动脉粥样硬化早期评估与管理(PRE-EMPT) (PRE-EMPT)

2026年11月6日 更新者:Duke University

前瞻性随机化动脉粥样硬化过早症评估与管理

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.

PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:

  1. A Screening Study - Participants will be assessed for plaque by one or both of these scans.

    • Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
    • Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
  2. A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.

    • Rosuvastatin 20 mg: a cholesterol-lowering medicine
    • Colchicine 0.5 mg: a medication that lowers inflammation

Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.

Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.

研究概览

详细说明

The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.

研究类型

介入性

注册 (估计的)

1500

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35205
        • 招聘中
        • University of Alabama at Birmingham
        • 首席研究员:
          • Kevin Riggs, MD
        • 接触:
      • Mobile、Alabama、美国、36608
        • 招聘中
        • Cardiology Associates
        • 接触:
        • 首席研究员:
          • Jason Cole, MD
    • California
      • Los Angeles、California、美国、90095
        • 招聘中
        • University of California, Los Angeles
        • 接触:
        • 首席研究员:
          • Karol Watson, MD
      • Los Angeles、California、美国、90502
        • 招聘中
        • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
        • 接触:
        • 首席研究员:
          • Matthew Budoff, MD
    • Georgia
      • Hiram、Georgia、美国、30141
        • 招聘中
        • Wellstar Kennestone Hospital
        • 首席研究员:
          • Frank Corrigan, MD
        • 接触:
    • Illinois
      • Chicago、Illinois、美国、60637
        • 招聘中
        • University of Chicago
        • 首席研究员:
          • Tamar Polonsky, MD
        • 接触:
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 尚未招聘
        • Johns Hopkins University
        • 接触:
        • 首席研究员:
          • Michael Blaha, MD
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital Brigham
        • 接触:
        • 首席研究员:
          • Michael Honigberg, MD
    • Minnesota
      • Duluth、Minnesota、美国、55805
    • New York
      • Mount Kisco、New York、美国、10549
        • 尚未招聘
        • Northern Westchester Hospital
        • 接触:
        • 首席研究员:
          • Dina Katz, MD
      • New York、New York、美国、10021
        • 招聘中
        • Weill Cornell Medicine
        • 接触:
        • 首席研究员:
          • Sam Kim, MD
      • New York、New York、美国、10016
        • 招聘中
        • New York University Langone
        • 首席研究员:
          • Harmony Reynolds, MD
        • 接触:
    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke University Hospital
        • 首席研究员:
          • Nishant Shah, MD
        • 接触:
      • Winston-Salem、North Carolina、美国、27157
        • 招聘中
        • Wake Forest University, Advocate Health
        • 首席研究员:
          • Michael Shapiro, MD
        • 接触:
    • Oregon
      • Portland、Oregon、美国、97239
        • 尚未招聘
        • Oregon Health and Sciences University
        • 接触:
        • 首席研究员:
          • Maros Ferencik, MD
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • 尚未招聘
        • Thomas Jefferson University
        • 接触:
        • 首席研究员:
          • Chris Chambers, MD
      • Pittsburgh、Pennsylvania、美国、15213
        • 招聘中
        • University of Pittsburgh Medical Center
        • 首席研究员:
          • Anum Saeed, MD
        • 接触:
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 招聘中
        • Medical University of South Carolina (MUSC)
        • 首席研究员:
          • Sheldon Litwin, MD
        • 接触:
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 尚未招聘
        • Vanderbilt University
        • 首席研究员:
          • Deepak Gupta, MD
        • 接触:
          • Gabriella Davies Thoppil, MD MPH
          • 电话号码:615-421-1143
          • 邮箱:g.thoppil@vumc.org
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • Houston Methodist Hospital
        • 接触:
        • 首席研究员:
          • Khurrrram Nasir, MD
    • Virginia
      • Charlottesville、Virginia、美国、22903
        • 招聘中
        • University of Virginia (UVA)
        • 接触:
        • 首席研究员:
          • Todd Villines, MD
      • Fairfax、Virginia、美国、22031
        • 尚未招聘
        • Inova Health System
        • 接触:
        • 首席研究员:
          • Jared Spitz, MD
    • Wisconsin
      • Marshfield、Wisconsin、美国、54449
        • 招聘中
        • Marshfield Clinical Research Institute
        • 接触:
        • 首席研究员:
          • Jeff VanWormer

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 60年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Women aged 40-60 years; Men aged 30-50 years
  2. Willing and able to provide informed consent and comply with study procedures
  3. Smart phone user
  4. Use of highly effective contraception by females with reproductive potential.
  5. CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
  6. Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab

Exclusion Criteria:

  1. Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
  2. Current symptoms thought to be from CAD
  3. PREVENT ASCVD 10-year risk ≥5% (if known)
  4. Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
  5. LDL-C ≥190mg/dL (most recent, if known)
  6. HIV (if known)
  7. Severe liver disease or untreated Hepatitis C infection (if known)
  8. Pregnancy, lactation or intending to become pregnant during the study period of 2 years
  9. eGFR <45mL/min/1.73m2 (if known)
  10. AST or ALT >1.5x the upper limit of normal (if known)
  11. BMI>40kg/m2 or unable to have a CCTA scan for any reason
  12. Allergy to iodinated intravenous contrast or other contraindication to CCTA
  13. Current or previous use of lipid lowering therapy or colchicine
  14. Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
  15. Systemic cancer undergoing active treatment
  16. PREVENT ASCVD 10-year risk ≥5%
  17. eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
  18. Hemoglobin A1c ≥6.5% per baseline labs
  19. LDL-C ≥190mg/dL per baseline labs
  20. Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
  21. Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
  22. Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:rosuvastatin 20mg plus colchicine-matched placebo

statin plus placebo (two pills once daily)

Statin

其他名称:
  • 克雷斯特

Placebo, non-active, drug-matched

实验性的:colchicine 0.5mg plus rosuvastatin-matched placebo

anti-inflammatory plus placebo (two pills once daily)

Placebo, non-active, drug-matched

Anti-inflammatory

其他名称:
  • 洛多科
实验性的:rosuvastatin 20mg plus colchicine 0.5mg

statin plus anti-inflammatory (two pills once daily)

Statin

其他名称:
  • 克雷斯特

Anti-inflammatory

其他名称:
  • 洛多科
安慰剂比较:placebo plus placebo

Placebo and placebo (two pills once daily)

Placebo, non-active, drug-matched

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
大体时间:2 years

Plaque volume in mm3 in each group

2 years

次要结果测量

结果测量
措施说明
大体时间
LDL-C(低密度脂蛋白胆固醇)变化
大体时间:基线至2年
基线至2年
非高密度脂蛋白胆固醇变化
大体时间:基线至2年
基线至2年
Number of participants with Drug Discontinuation
大体时间:Up to 2 years

Drug Tolerability outcome

Up to 2 years
Overall drug treatment adherence
大体时间:Up to 2 years

Number of days on study drugs

Up to 2 years
Safety events of special interest
大体时间:Up to 2 years

Number of safety events of special interest per group

Up to 2 years
Total plaque volume
大体时间:Up to 2 years

Plaque volume in mm3 per group

Up to 2 years
Low-attenuation plaque volume
大体时间:Up to 2 years

Low attenuated plaque volume in mm3 per group

Up to 2 years
Calcified plaque volume
大体时间:Up to 2 years

Calcified plaque volume in mm3 per group

Up to 2 years
Number of participants with stenosis
大体时间:Up to 2 years

Number of participants with stenosis per group

Up to 2 years
Segment involvement score
大体时间:Up to 2 years

Average score per group

Up to 2 years
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
大体时间:Up to 2 years

Number of participants with each plaque composition description per group

Up to 2 years
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
大体时间:Up to 2 years

Number of participants with each plaque feature (high-risk) per group

Up to 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月21日

初级完成 (估计的)

2031年7月1日

研究完成 (估计的)

2031年7月1日

研究注册日期

首次提交

2025年11月14日

首先提交符合 QC 标准的

2025年11月14日

首次发布 (实际的)

2025年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅